Track the Colinz Laboratories stock price and the full directors' dealings record of the company, a listed equity based in India. Shares are listed on the IN market, under the supervision of SEBI (PIT + SAST). Market capitalisation: €199m. The latest transaction was disclosed on 27 May 2026 (Acquisition). Among the most active insiders: Padam Dugar & Others. The full history is openly available.
7
Insider Decl.
n/a
Thresholds
€169,590
5 ops.
Buy Volume
€169,590
2 ops.
Sell Volume
32Σ signal
Buys €169,590€169,590 Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 17,016 of 29,062 companies
47.0
score / 100
Value
28
Quality
66
FCF yld-9.7%
Earn yld2.8%
EV/EBITDA23.1x
ROE5.3%
Gross mgn68%
Net mgn7.6%
Debt/EBITDA0.8x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
316,000 shares@ ₹50.00100.0% of flowEquity SharesOff MarketSEBI:97534609ad181eee4de1a4737165bdee04f65118
Canonical exit: 24 Aug 2026 (T+90)
7 of 7 declarations
Acerca de Colinz Laboratories
Colinz Laboratories es una empresa que cotiza en la XBOM, especializada en el desarrollo y la fabricación de productos farmacéuticos. Se centra en la innovación y la investigación para mejorar la salud de los pacientes.